A Study to Test the Interaction of Padsevonil With Oral Contraceptives in Healthy Female Participants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-23

Study Completion Date

2020-05-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to investigate the effect of steady-state padsevonil on the pharmacokinetic of a single dose oral contraceptive.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Test the Blood Concentration of 4 Padsevonil Product Variants and the Effect of Food on Padsevonil

NCT04283136

Healthy Participants Epilepsy

WITHDRAWN PHASE1

Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

NCT03370120

Drug-Resistant Epilepsy Focal-Onset Seizures

TERMINATED PHASE2

An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy

NCT02625090

Highly Drug-resistant Focal Epilepsy

TERMINATED PHASE2

A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

NCT03739840

Drug-Resistant Epilepsy Focal-Onset Seizures

TERMINATED PHASE3

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

NCT03373383

Drug-resistant Epilepsy Focal-Onset Seizures

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Female Participants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oral contraceptive

Participants will receive oral contraceptive in Period 2 of Sequence A and Period 1 of Sequence B of Part 1 and Part 2.

Group Type EXPERIMENTAL

Microgynon 30®

Intervention Type DRUG

Study Medication: Microgynon 30® Dosage formulation: Oral tablets Dose: Ethinyl estradiol 30 µg + levonorgestrel 150 µg

Oral contraceptive + padsevonil

Participants will receive padsevonil + oral contraceptive in Period 1 of Sequence A and Period 2 of Sequence B of Part 1 and Part 2.

Group Type EXPERIMENTAL

Padsevonil

Intervention Type DRUG

Study Medication: Padsevonil Dosage formulation: Oral tablets; 400 mg BID (Part 1) and 200 mg BID (Part 2)

Microgynon 30®

Intervention Type DRUG

Study Medication: Microgynon 30® Dosage formulation: Oral tablets Dose: Ethinyl estradiol 30 µg + levonorgestrel 150 µg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Padsevonil

Study Medication: Padsevonil Dosage formulation: Oral tablets; 400 mg BID (Part 1) and 200 mg BID (Part 2)

Intervention Type DRUG

Microgynon 30®

Study Medication: Microgynon 30® Dosage formulation: Oral tablets Dose: Ethinyl estradiol 30 µg + levonorgestrel 150 µg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant must be aged 18 years of age or greater, at the time of signing the informed consent
* Participant must be a premenopausal female with no indication of abnormal or gestational/lactational hypothalamic-pituitary-ovarian function. Menopause will be defined for the purpose of this study as amenorrhea of ≥12 months for which no other reason has been identified
* Participant must not be pregnant or breastfeeding. Participant must agree to use an effective form of contraception (other than hormonal methods) for the duration of the Treatment Period and for at least 90 days (or 5 terminal half-lives) after the last dose of study medication
* Participant must be in good physical and mental health as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring
* Participant must have body weight of at least 45 kg and body mass index within the range 18 to 30 kg/m\^2 (inclusive)

Exclusion Criteria

* Participant has a history of discontinued use of oral contraceptives (OC) for medical reasons
* Participant has any medical reason that would contraindicate the administration of OC (per label)
* Participant has used any of the following within the specified time period prior to first dose of study medication:

1. Oral contraceptive or oral hormone replacement therapy within prior 30 days
2. Implanted hormonal contraceptives within prior 6 months
3. Injectable contraceptives within prior 12 months
4. Topical controlled-delivery contraceptives within prior 3 months
5. Hormone-releasing intrauterine devices ('coils') within prior 3 months
* Participant has other relevant gynecological disorders (such as premature ovarian failure or endometriosis)
* Participant has any clinically relevant electrocardiogram (ECG) finding at the Screening Visit or at Baseline (Day -1) that, in the opinion of the Investigator, increases the risks associated with participating in the study. In addition, any study participant with any of the following findings will be excluded:

1. QT interval corrected for heart rate using Bazett's formula (QTcB) or Fridericia's formula (QTcF) \>450 ms in 2 of 3 ECG recordings;
2. other conduction abnormalities (defined as PR interval ≥220 ms);
3. irregular rhythms other than sinus arrhythmia or occasional, rare supraventricular or rare ventricular ectopic beats. In case of an out-of-range result, 1 repeat will be allowed. If the result is out-of-range again, the study participant cannot be included

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes